EGFR and non-small cell lung carcinoma: In a retrospective single-institution study, local therapy (either surgery or radiotherapy) for BM in EGFR-mutant (17 treated with erlotinib) or ALK-rearranged (38 treated with crizotinib) NSCLC patients and CNS progression allowed continuation of therapy for an additional 7.1 months (137).